Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan clinical oncology group study JCOG0211

Journal of Clinical Oncology

Volumn 27, Issue 33, 2009, Pages 5594-5600

  Yamaguchi, Motoko ^a   Tobinai, Kensei ^a   Oguchi, Masahiko ^a   Ishizuka, Naoki ^a   Kobayashi, Yukio ^a   Isobe, Yasushi ^a   Ishizawa, Kenichi ^a   Maseki, Nobuo ^a   Itoh, Kuniaki ^a   Usui, Noriko ^a   Wasada, Izumi ^a   Kinoshita, Tomohiro ^a   Ohshima, Koichi ^a   Matsuno, Yoshihiro ^a   Terauchi, Takashi ^a   Nawano, Shigeru ^a   Ishikura, Satoshi ^a   Kagami, Yoshikazu ^a   Hotta, Tomomitsu ^a   Oshimi, Kazuo ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; ANTINEOPLASTIC AGENT; ICE PROTOCOL 2;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DRUG DOSE ESCALATION; DYSPHAGIA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPOKALEMIA; INFECTION; KERATITIS; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION INJURY; RECOMMENDED DRUG DOSE; SEX RATIO; SIDE EFFECT; STOMATITIS; T CELL LYMPHOMA; THROMBOCYTOPENIA; WEIGHT REDUCTION; ADJUVANT THERAPY; AGE; CANCER STAGING; COMPUTER ASSISTED RADIOTHERAPY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; IMMUNOHISTOCHEMISTRY; JAPAN; KAPLAN MEIER METHOD; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEEDLE BIOPSY; NK T CELL LYMPHOMA; NOSE TUMOR; PATHOLOGY; PROBABILITY; PROPORTIONAL HAZARDS MODEL; RADIATION DOSE; RISK ASSESSMENT; SEX DIFFERENCE; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; CARBOPLATIN; COMBINED MODALITY THERAPY; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; IMMUNOHISTOCHEMISTRY; JAPAN; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; NOSE NEOPLASMS; PROBABILITY; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, CONFORMAL; RISK ASSESSMENT; SEX FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 73949086783     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.8295     Document Type: Article

References (48)

1. Jaffe ES, Harris NL, Stein H, et al: World Health Organization classification of tumours: Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France, IARC Press, 2001
2. Swerdlow SH, Campo E, Harris NL, et al: WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France, IARC, 2008
3. Oshimi K: Progress in understanding and managing natural killer-cell malignancies. Br J Haematol 139:532-544, 2007
4. Suzuki R, Takeuchi K, Ohshima K, et al: Extranodal NK/T-cell lymphoma: Diagnosis and treatment cues. Hematol Oncol 26:66-72, 2008
5. Anderson JR, Armitage JO, Weisenburger DD: Epidemiology of the non-Hodgkin's lymphomas: Distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 9:717-720, 1998
6. Oshimi K, Kawa K, Nakamura S, et al: NK-cell neoplasms in Japan. Hematology 10:237-245, 2005
7. Au WY, Weisenburger DD, Intragumtornchai T, et al: Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: A study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 113:3931-3937, 2009
8. Harabuchi Y, Yamanaka N, Kataura A, et al: Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 335: 128-130, 1990
9. Jaffe ES, Chan JK, Su IJ, et al: Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas: Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 20:103-111, 1996
10. Yamaguchi M, Kita K, Miwa H, et al: Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 76:2351-2356, 1995
11. Egashira M, Kawamata N, Sugimoto K, et al: P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood 93:599-606, 1999
12. Drenou B, Lamy T, Amiot L, et al: CD3-CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance. Blood 89:2966-2974, 1997
13. Yamaguchi M, Suzuki R, Kwong YL, et al: Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 99:1016-1020, 2008
14. Kim BS, Kim DW, Im SA, et al: Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone. Ann Oncol 20:121-128, 2009
15. Miller TP, Dahlberg S, Cassady JR, et al: Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 339:21-26, 1998
16. Ribrag V, Ell Hajj M, Janot F, et al: Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx. Leukemia 15:1123-1126, 2001
17. Cheung MM, Chan JK, Lau WH, et al: Primary non-Hodgkin's lymphoma of the nose and nasopharynx: Clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 16:70-77, 1998
18. Yamaguchi M, Ogawa S, Nomoto Y, et al: Treatment outcome of nasal NK-cell lymphoma: A report of 12 consecutively-diagnosed cases and a review of the literature. J Clin Exp Hematop 41:93-99, 2001
19. Kim WS, Song SY, Ahn YC, et al: CHOP followed by involved field radiation: Is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol 12:349-352, 2001
20. Kim GE, Cho JH, Yang WI, et al: Angiocentric lymphoma of the head and neck: Patterns of systemic failure after radiation treatment. J Clin Oncol 18:54-63, 2000
21. Cheung MM, Chan JK, Lau WH, et al: Early stage nasal NK/T-cell lymphoma: Clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 54: 182-190, 2002
22. Schaake-Koning C, van den Bogaert W, Dalesio O, et al: Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524-530, 1992
23. Ohtsu A, Boku N, Muro K, et al: Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 17:2915-2921, 1999
24. Bernier J, Domenge C, Ozsahin M, et al: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945-1952, 2004
25. Lee J, Suh C, Park YH, et al: Extranodal natural killer T-cell lymphoma, nasal-type: A prognostic model from a retrospective multicenter study. J Clin Oncol 24:612-618, 2006
26. Okamoto M, Maruyama F, Tsuzuki M, et al: Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide and carboplatin. Rinsho Ketsueki 35:635-641, 1994
27. Imashuku S, Kuriyama K, Teramura T, et al: Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol 19:2665-2673, 2001
28. Shikama N, Ikeda H, Nakamura S, et al: Localized aggressive non-Hodgkin's lymphoma of the nasal cavity: A survey by the Japan Lymphoma Radiation Therapy Group. Int J Radiat Oncol Biol Phys 51:1228-1233, 2001
29. Koom WS, Chung EJ, Yang WI, et al: Angiocentric T-cell and NK/T-cell lymphomas: Radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys 59:1127-1137, 2004
30. Isobe K, Uno T, Tamaru J, et al: Extranodal natural killer/T-cell lymphoma, nasal type: The significance of radiotherapeutic parameters. Cancer 106: 609-615, 2006
31. Oguchi M, Kagami Y, Ishikura S, et al: Upfront radiotherapy with concurrent chemotherapy for localized nasal NK/T-cell lymphoma: Radiotherapy quality assurance (QA) review in Japan Clinical Oncology Group (JCOG) trial 0211. Int J Radiat Oncol Biol Phys 72:S474, 2008 (abstr 2682)
32. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17:1244-1253, 1999
33. Yamaguchi M, Oguchi M, Tobinai K, et al: Phase I/II study of concurrent chemoradiotherapy for newly-diagnosed, localized nasal NK/T-cell lymphoma: Results of a phase I portion of JCOG0211-DI. Blood 106:754A, 2005 (abstr 2685)
34. A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
35. Aviles A, Diaz NR, Neri N, et al: Angiocentric nasal T/natural killer cell lymphoma: A single centre study of prognostic factors in 108 patients. Clin Lab Haematol 22:215-220, 2000
36. Li YX, Yao B, Jin J, et al: Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 24:181-189, 2006
37. Nomura E, Isoda K, Yamanaka K, et al: Extra nodal NK/T-cell lymphoma nasal type that responded to DeVIC combination chemotherapy. J Dermatol 32:204-209, 2005
38. Lee KW, Yun T, Kim DW, et al: First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/- radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. Leuk Lymphoma 47:1274-1282, 2006
39. Yokoyama H, Yamada MF, Ishizawa K, et al: Successful treatment of advanced extranodal NK/T cell lymphoma with unrelated cord blood transplantation. Tohoku J Exp Med 211:395-399, 2007
40. Girinsky T, Lapusan S, Ribrag V, et al: Phase II study of concomitant chemoradiotherapy in bulky refractory or chemoresistant relapsed lymphomas. Int J Radiat Oncol Biol Phys 61:476-479, 2005
41. Wendt TG, Grabenbauer GG, Rodel CM, et al: Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. J Clin Oncol 16:1318-1324, 1998
42. Garden AS, Glisson BS, Ang KK, et al: Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: Toxicities and responses. J Clin Oncol 17:2390-2395, 1999
43. Yong W, Zheng W, Zhang Y, et al: L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol 78:163-167, 2003
44. Jaccard A, Petit B, Girault S, et al: L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol 20:110-116, 2009
45. Au WY, Lie AK, Liang R, et al: Autologous stem cell transplantation for nasal NK/T-cell lymphoma: A progress report on its value. Ann Oncol 14:1673-1676, 2003
46. Lee J, Au WY, Park MJ, et al: Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: A multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant 14:1356-1364, 2008
47. Lei KI, Chan LY, Chan WY, et al: Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma. Clin Cancer Res 8:29-34, 2002
48. Au WY, Pang A, Choy C, et al: Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 104:243-249, 2004